New Republic Capital’s GSK GSK Stock Holding History

New Republic Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,612	Closed	-$277K	–	343
2025 Q4	$277K	Buy	+5,612	New	+$262K	0.07%	227

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

New Republic Capital's GSK Position: Q1 2026 in Review

New Republic Capital sold out of GSK (GSK) in Q1 2026, closing a stake of 5,612 shares — an estimated $277K sold.

New Republic Capital first reported a position in GSK in Q4 2025 and held it in 1 quarter. The position peaked at $277K in Q4 2025. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

New Republic Capital reported no remaining GSK position as of Q1 2026 after selling out during the quarter.
New Republic Capital sold 5,612 GSK shares in Q1 2026, an estimated $277K.
New Republic Capital first reported a position in GSK in Q4 2025 and held it in 1 quarter.
New Republic Capital's GSK position peaked at $277K in Q4 2025.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on New Republic Capital's 13F filing for Q1 2026, filed 1 May 2026.